CIK 0001896212 · <br>Emerging growth company
CDT Equity Inc.
Sign in to watch- Ticker
- CDT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 873272543
- Phone
- (646) 491 9132
- Business address
- 4851 TAMIAMI TRAIL NORTH, SUITE 200, NAPLES, FL, 34103
- Former names
- CONDUIT PHARMACEUTICALS INC., Murphy Canyon Acquisition Corp.
Securities
- CDT Common Stock Nasdaq
- CDTTW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 2 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-11 | Regan Andrew Director | Sale | −300,000 | $0.29 | $87K | 14,331,139 |
| 2024-07-10 | Regan Andrew Director | Sale | −150,000 | $0.33 | $50K | 15,214,091 |
| 2024-07-09 | Regan Andrew Director | Sale | −77,681 | $0.44 | $34K | 15,364,091 |
| 2024-07-08 | Regan Andrew Director | Sale | −35,923 | $0.51 | $18K | 15,441,772 |
| 2024-07-03 | Regan Andrew Director | Sale | −1,000 | $0.64 | $640 | 15,477,695 |
| 2024-06-14 | Regan Andrew Director | Other disposition | −1,100,000 | 30,048,454 | ||
| 2024-06-14 | Regan Andrew Director | Other acquisition | +1,100,000 | 15,478,695 | ||
| 2024-06-11 | Farley Chele Chiavacci Director | Grant or award | +37,272 | 52,272 | ||
| 2024-06-11 | Bligh James Interim CFO | Grant or award | +37,272 | 37,272 | ||
| 2024-05-15 | Sragovicz Adam Chief Financial Officer | Returned to the company | −74,545 | 0 | ||
| 2024-05-13 | McNealey Jennifer Isacoff Director | Returned to the company · Stock Option (Right to Buy) | −65,000 | $5.51 | $358K | 0 |
| 2024-04-22 | Farley Chele Chiavacci Director | Grant or award · Warrant (Right to buy) | +3,000 | 3,000 | ||
| 2024-04-22 | Farley Chele Chiavacci Director | Purchase · Warrant (Right to buy) | +200,332 | 203,332 | ||
| 2024-04-22 | Lewis-Hall Freda C Director | Grant or award · Warrant (Right to buy) | +400,664 | 400,664 | ||
| 2024-04-22 | Lewis-Hall Freda C Director | Grant or award · Warrant (Right to buy) | +103,397 | 103,397 | ||
| 2024-04-22 | Tapolczay David Chief Executive Officer | Grant or award · Warrant (Right to buy) | +400,664 | 400,664 | ||
| 2024-04-22 | Tapolczay David Chief Executive Officer | Sale · Warrant (Right to buy) | −200,332 | 200,332 | ||
| 2023-12-01 | Lewis-Hall Freda C Director | Grant or award · Stock Option (Right to Buy) | +65,000 | $5.51 | $358K | 65,000 |
| 2023-12-01 | Tapolczay David Director | Grant or award · Stock Option (Right to Buy) | +298,179 | $5.51 | $1.6M | 298,179 |
| 2023-12-01 | Sragovicz Adam Chief Financial Officer | Grant or award | +74,545 | 74,545 |
Page 4 of 5 · 90 trades